...
首页> 外文期刊>Bioorganic and Medicinal Chemistry Letters >Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part II. Identification of the 1,3,8-triazaspiro(4,5)decan-4-one privileged structure that engenders PLD2 selectivity.
【24h】

Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part II. Identification of the 1,3,8-triazaspiro(4,5)decan-4-one privileged structure that engenders PLD2 selectivity.

机译:设计和合成同工型选择性磷脂酶D(PLD)抑制剂。第二部分识别导致PLD2选择性的1,3,8-triazaspiro(4,5)decan-4-one特权结构。

获取原文
获取原文并翻译 | 示例
           

摘要

This Letter describes the synthesis and structure-activity relationships (SAR) of isoform-selective PLD inhibitors. By virtue of the installation of a 1,3,8-triazaspiro[4,5]decan-4-one privileged structure, PLD inhibitors with nanomolar potency and an unprecedented 40-fold selectivity for PLD2 over PLD1 were developed. Interestingly, SAR for this diverged from our earlier efforts, and dual PLD1/2 inhibitors were also discovered within this series.
机译:这封信描述了同工型选择性PLD抑制剂的合成和构效关系(SAR)。通过安装1,3,8-三氮杂螺[4,5] decan-4-one特权结构,开发了具有纳摩尔浓度的PLD抑制剂,其对PLD2的选择性是PLD1的40倍。有趣的是,为此,SAR与我们先前的努力背道而驰,并且在该系列中也发现了双重PLD1 / 2抑制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号